ANI Pharmaceuticals Launches Pimozide Tablets with 180-Day Exclusivity
Event summary
- ANI Pharmaceuticals launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap®, with 180-day CGT exclusivity.
- U.S. annual sales for Pimozide Tablets are approximately $3.1 million, based on February 2026 IQVIA data.
- ANI Pharmaceuticals is a diversified biopharmaceutical company focused on Rare Disease, Generics, and Brands businesses.
The big picture
ANI Pharmaceuticals' launch of Pimozide Tablets underscores its strategy of bringing limited-competition generic products to market. This move aligns with broader industry trends where biopharmaceutical companies seek to balance innovation with cost-effective generic alternatives. The 180-day exclusivity period provides a strategic window to capture market share before potential competitors enter, but the long-term success will depend on ANI's ability to navigate regulatory landscapes and maintain operational efficiency.
What we're watching
- Market Exclusivity
- The 180-day CGT exclusivity period will shield ANI from immediate competition, but the pace at which competitors enter the market post-exclusivity will determine long-term revenue.
- Regulatory Risks
- The FDA's actions and potential policy changes could impact ANI's ability to maintain exclusivity and commercialize its products effectively.
- Revenue Growth
- Whether ANI can leverage this launch to drive significant revenue growth in its Generics business, given the relatively modest $3.1 million annual sales figure.
Related topics